Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients

被引：5
|
作者：
Thomas, Melissa K.
Nikooienejad, Amir
Bray, Ross
Cui, Xuewei
Wilson, Jonathan M.
Duffin, Kevin L.
Milicevic, Zvonko
Haupt, Axel
Robins, Deborah A.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-980-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
980-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycaemic control and body weight in Japanese patients with type 2 diabetes
    Benson, C. T.
    Ohwaki, K.
    Furihata, K.
    Mimura, H.
    Oura, T.
    Imaoka, T.
    DIABETOLOGIA, 2019, 62 : S353 - S353
  • [22] Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
    Karagiannis, Thomas
    Avgerinos, Ioannis
    Liakos, Aris
    Del Prato, Stefano
    Matthews, David R.
    Tsapas, Apostolos
    Bekiari, Eleni
    DIABETOLOGIA, 2022, 65 (08) : 1251 - 1261
  • [23] Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
    Thomas Karagiannis
    Ioannis Avgerinos
    Aris Liakos
    Stefano Del Prato
    David R. Matthews
    Apostolos Tsapas
    Eleni Bekiari
    Diabetologia, 2022, 65 : 1251 - 1261
  • [24] Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes
    Rosenstock, Julio
    Robins, Deborah A.
    Duffin, Kevin L.
    Wilson, Jonathan M.
    Mather, Kieren J.
    Banerjee, Hiya
    Lin, Yanzhu
    Eyde, Sarah
    Kazda, Christof M.
    Konig, Manige
    DIABETES, 2024, 73
  • [25] Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
    Lee, Clare J.
    Mao, Huzhang
    Thieu, Vivian T.
    Lando, Laura Fernandez
    Thomas, Melissa K.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (05)
  • [26] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Martin, Jennifer
    Loghin, Corina
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1049 - 1059
  • [27] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Ma, Xiaosu
    Martin, Jennifer A.
    Benson, Charles T.
    CLINICAL PHARMACOKINETICS, 2022, 61 (07) : 1057 - 1067
  • [28] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Jennifer Martin
    Corina Loghin
    Clinical Pharmacokinetics, 2021, 60 : 1049 - 1059
  • [29] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Xiaosu Ma
    Jennifer A. Martin
    Charles T. Benson
    Clinical Pharmacokinetics, 2022, 61 : 1057 - 1067
  • [30] Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
    Nowak, Mariusz
    Nowak, Wojciech
    Grzeszczak, Wladyslaw
    ENDOKRYNOLOGIA POLSKA, 2022, 73 (04) : 745 - 755
12345